Literature DB >> 22938493

Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2.

Fatemeh Kalalinia1, Fatemeh Elahian, Mitra Hassani, Jamal Kasaeeian, Javad Behravan.   

Abstract

Recent studies have indicated a link between levels of cyclooxygenase-2 (COX-2) and development of the multidrug resistance (MDR) phenotype. The ATP-binding cassette sub-family G member 2 (ABCG2) is a major MDR-related transporter protein that is frequently overexpressed in cancer patients. In this study, we aimed to evaluate any positive correlation between COX-2 and ABCG2 gene expression using the COX-2 inducer 12-O-tetradecanoylphorbol-13-acetate (TPA) in human breast cancer cell lines. ABCG2 mRNA and protein expression was studied using real-time RT-PCR and flow cytometry, respectively. A significant increase of COX-2 mRNA expression (up to 11-fold by 4 h) was induced by TPA in MDA-MB-231 cells, this induction effect being lower in MCF-7 cells. TPA caused a considerable increase up to 9-fold in ABCG2 mRNA expression in parental MCF-7 cells, while it caused a small enhancement in ABCG2 expression up to 67 % by 4 h followed by a time-dependent decrease in ABCG2 mRNA expression in MDA-MB-231 cells. TPA treatment resulted in a slight increase of ABCG2 protein expression in MCF-7 cells, while a time-dependent decrease in ABCG2 protein expression was occurred in MDA-MB-231 cells. In conclusion, based on the observed effects of TPA in MDA-Mb-231 cells, it is proposed that TPA up-regulates ABCG2 expression in the drug sensitive MCF-7 breast cancer cell line through COX-2 unrelated pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938493     DOI: 10.7314/apjcp.2012.13.6.2979

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Protein kinase Cα mediates erlotinib resistance in lung cancer cells.

Authors:  Mahlet B Abera; Marcelo G Kazanietz
Journal:  Mol Pharmacol       Date:  2015-02-27       Impact factor: 4.436

Review 2.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

3.  Evaluation the interaction of ABC multidrug transporter MDR1 with thymoquinone: substrate or inhibitor?

Authors:  Vahideh Keyvani; Zeinab Nasserifar; Mohammad-Reza Saberi; Seyed Ahmad Mohajeri; Sepideh Arabzadeh; Farajollah Shahriari Ahmadi; Hossein Hosseinzadeh; Seyedeh Mahya Shariat Razavi; Fatemeh Kalalinia
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

4.  Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer.

Authors:  Mahnaz Nourbakhsh; Mahmoud Reza Jaafari; Hermann Lage; Khalil Abnous; Fatemeh Mosaffa; Ali Badiee; Javad Behravan
Journal:  Iran J Basic Med Sci       Date:  2015-04       Impact factor: 2.699

5.  Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines.

Authors:  Fatemeh Kalalinia; Fatemeh Elahian; Fatemeh Mosaffa; Javad Behravan
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

6.  Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines

Authors:  Taheri Taheri; Khadijeh Jamialahmadi; Fatemeh Khadijeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

7.  Crocin Increases Gastric Cancer Cells' Sensitivity to Doxorubicin.

Authors:  Seyedeh Mahya Shariat Razavi; Reyhaneh Mahmoudzadeh Vaziri; Gholamreza Karimi; Sepideh Arabzadeh; Vahideh Keyvani; Javad Behravan; Fatemeh Kalalinia
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

Review 8.  The multiple facets of drug resistance: one history, different approaches.

Authors:  Evandro Luís Niero; Bianca Rocha-Sales; Camila Lauand; Beatriz Araujo Cortez; Marcelo Medina de Souza; Paula Rezende-Teixeira; Marcel Shiniti Urabayashi; Adam Arai Martens; Jorge Henrique Neves; Gláucia Maria Machado-Santelli
Journal:  J Exp Clin Cancer Res       Date:  2014-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.